Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Condition:   Acute Lymphoblastic Leukemia ,Lymphomas Intervention:   Biological: Anti-CD19 CAR-T Sponsor:   The First Affiliated Hospital of Nanchang University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials